Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

By F. Houssiau, C. Vasconcelos, D. D'cruz, G. Sebastiani, Enrique de Ramon Garrido Ed, M. Danieli, D. Abramovicz, D. Blockmans, A. Mathieu, H. Direşkeneli and 12 more. Arthritis & Rheumatism, 2002

1,039 citations recorded by the source corpus.

Subfields: Pathology and Forensic Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/f6fe1b6ff3b72d08161b8e0f38ecd0034e9ab5c9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Rheumatology

Citations in the corpus

KDIGO Clinical Practice Guideline for Glomerulonephritis (2012, background): “cyclophosphamide 500 mg every 2 weeks for 3 months (Regimen B, sometimes called the ‘‘Euro-Lupus regimen’’) had equivalent efficacy to Regimen A in an RCT in Caucasians.(603,604) However, few patients in the Euro-Lupus trial had severe kidney disease, defined as rapidly progressive kidney failure an”
American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis (2012, background): “In those European study patients, the low- and high-dose regimens were equivalent in efficacy (40,41), and serious infections were less frequent with the lower doses.”
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. (2009, background): “1104 Journal of the American Society of Nephrology J Am Soc Nephrol 20: 1103–1112, 2009 aAnti-dsDNA, antibodies reactive to double-stranded DNA; C3, complement factor 3; C4, complement factor 4. bRace self-reported as black (46), Mexican-Mestizo (28), mixed race (9), Hispanic (3), North African (2),”